Block, V. J.
Lizée, A.
Crabtree-Hartman, E.
Bevan, C. J.
Graves, J. S.
Bove, R.
Green, A. J.
Nourbakhsh, B.
Tremblay, M.
Gourraud, P.-A.
Ng, M. Y.
Pletcher, M. J.
Olgin, J. E.
Marcus, G. M.
Allen, D. D.
Cree, B. A. C.
Gelfand, J. M.
Funding for this research was provided by:
National Center for Advancing Translational Sciences (KL2TR000143)
Article History
Received: 19 September 2016
Revised: 2 November 2016
Accepted: 3 November 2016
First Online: 28 November 2016
Compliance with ethical standards
:
: Valerie J Block has no disclosures.Antoine Lizée has no disclosures.Elizabeth Crabtree-Hartman has received educational grants from the MS Foundation, Teva neurosciences, and Biogen. She has served as a consultant to Genzyme, Teva and Novartis. She is on the Speakers Bureau for Genzyme, Teva and Biogen.Carolyn J Bevan has no disclosures.Jennifer Graves has current research grants from Race to Erase MS, National MS Society, Genentech, and Biogen.Riley Bove has no disclosures.Ari Green has received research grants from the NMSS, NIH, Novartis and Inception 5 Sciences. He has served on an end point adjudication committee for Mediimmune and a steering committee for OCTIMs. He has served as an expert witness for Mylan and Amneal. He also is on the Scientific Advisory Board of Bionure and Inception Sciences.Matthew Tremblay has no disclosures.Bardia Nourbakhsh has received research support from American Brain Foundation, Biogen and National MS Society.Pierre-Antoine Gourraud has no disclosures.Madelena Ng has no disclosures.Jeffrey Olgin has no disclosures.Gregory M Marcus has no disclosures.Jeffrey M Pletcher has no disclosures.Diane D Allen has received compensation as an instructor for the Neurologic Physical Therapy Residency Program at Kaiser Redwood City. She has also received compensation for co-developing an online continuing education course in rehabilitation for people with multiple sclerosis for Western Schools.Bruce C Cree has received personal compensation for consulting from Abbvie, Biogen, EMD Serono, MedImmune, Novartis, Sanofi Genzyme, Shire and Teva.Jeffrey M Gelfand has received personal compensation for consulting on a scientific advisory board for MedImmune and Genentech, research support to UCSF from Quest Diagnostics for development of a dementia care pathway, and personal compensation for medical legal consulting as an expert witness.
: National Center for Advancing Translational Sciences of NIH (KL2TR000143) (JMG).